FMP

FMP

Enter

ME - 23andMe Holding...

photo-url-https://images.financialmodelingprep.com/symbol/ME.png

23andMe Holding Co.

ME

NASDAQ

23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.

3.17 USD

-0.04 (-1.26%)

Historical Prices

From:

To:

We are unable to load the chart at this time.

fmp-logo

About

ceo

Ms. Anne Wojcicki

sector

Healthcare

industry

Medical - Diagnostics & Research

exchange

NASDAQ

Description

23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas...

CIK

0001804591

ISIN

US90138Q1085

CUSIP

90138Q108

Address

349 Oyster Point Boulevard

Phone

650 938 6300

Country

US

Employee

560

IPO Date

Nov 23, 2020

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

ME Financial Summary

CIK

0001804591

Exchange

NASDAQ

Industry

Medical - Diagnostic...

Sector

Healthcare

CUSIP

90138Q108

ISIN

US90138Q1085

Country

US

Price

3.17

Beta

1.26

Volume Avg.

341.91k

Market Cap

86.65M

Shares

-

52-Week

2.655-19.34

DCF

-2.31

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-0.03

P/B

-

Website

https://www.23andme.com

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

Latest ME News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep